Impact of Treatment on the Quality of Life in Patients with Critical Limb Ischaemia  by Hernández-Osma, E. et al.
Impact of Treatment on the Quality of Life in Patients with
Critical Limb Ischaemia
E. HernaÂndez-Osma, M. A. Cairols, X. MartõÂ, E. Barjau and S. Riera
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Aim: the purpose of this study was to assess the quality of life (QOL) in patients with critical lower limb ischaemia (CLI),
and its modification after three types of therapeutical outcomes.
Materials and methods: between January and December 2000 52 patients (36 male, mean age 68 years) treated for critical
limb ischaemia (CLI) completed the Short Form (SF)-36 on admission and then 6 and 12 months later. Patients were divided
in the 3 groups: Group I: revascularisation; Group II: major amputation; Group III: conservative treatment. Trends for each
dimension over the follow-up and the effect of treatment group were assessed by an analysis of variance with repeated
measurements.
Results: on admission, patients with CLI had a significantly worse health-related quality of life than a control population.
Although some domains improved, some also deteriorated between baseline and 12 months and there was no significant
difference between the three treatment groups.
Conclusions: our results suggest that changes in dimensions of QOL obtained by limb revascularisation do not differ from
those of other therapeutic approaches.
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Critical lower limb ischaemia (CLI) is a major
health and socio-economic problem with poor prog-
nosis.1,2 To date few studies have examined the rela-
tionships between health-related quality of life and
treatment.3±5
The purpose of this study is to assess the changes in
the QOL in a population of CLI patients after three
different types of treatments.
Material and Methods
The Medical Outcomes Study Short Form 36 (SF36)
has 36 parameters divided in eight dimensions: phys-
ical activity, social activity, state of general health,
emotional state, limitations due to physical problems
as well as due to emotional problems, vitality and
pain. Each parameter is valued in a scale from 0 to
100, in which 0 means no QOL and 100 maximum
QOL.6±9Please address all correspondence to: M. A. Cairols, Ciutat Sanitaria
i Universitaria de Bellvitge, Faixa Llarga s/n 08907 L'Hospitalet de
Llobregat, Barcelona, Spain.
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with CLI were admitted to our department. One
hundred patients were excluded from the study due to
previous treatments. Another 30 patients were
excluded due to mental disease (unable to fulfil the
questionnaire) and short life expectancy due to
terminal diseases. And 13 patients refused to comply
with the protocol. Finally 52 patients (36 males, mean
age 68 [range 38±90] years) completed the SF-36
on admission and again at 6 and 12 months.
Patients were divided in three groups according to the
intervention:
Group I: patients underwent limb revascularisation;
Group II: patients underwent a major limb amputation;
Group III: patients treated medically with sympathect-
omy, or prostaglandin with or without minor amputa-
tion. Categorical variables were compared among
groups by Chi-square test.
The SF-36 questionnaire components were compared
according to the type of treatment result by Analysis
of Variance. The Cronbach's Alpha coefficient10 was
calculated to evaluate the internal consistency of the
test SF-36 using the first questionnaire. The value
of the coefficient ranges from 0 to 1, values above
0.511 are recommended as the minimum to ensure anll rights reserved.
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36 for dead patients at 6 or 12-month visit were
replaced by the values obtained by Diehr's method12
in order to keep statistical power. This approach was
undertaken in order to facilitate the intention to
treat analysis. Trends for each dimension over the
follow-up and the effect of treatment group were
assessed by an analysis of variance with repeated
measurements.
Results
Our patients (Table 1) had a worse baseline QOL than
the age-adjusted Spanish reference population13 for all
the dimensions. The most affected dimension was the
`` role-physical'' (median 10), and the least affected
`` mental health'', (median 64).
Limb revascularisation was performed in 30
(58%) patients: 6 aorto-bifemoral grafts, 15 bypassesTable 1. Spanish version of the SF-36 on admission 6 and 12 months
SF-36 Physical
functioning
Role
physical
Bodily
pain
Ge
he
Spanish pop. 65 69 68 53
Admission
median
30 10 34 36
range 0±80 0±100 0±100 6±
6 months
median
34 45 29 35
range 0±95 0±100 20±100 10
12 months
median
28 41 24 36
range 0±95 0±100 12±100 20
pa 0.20 0.09 0.85 0.8
pb 0.37 0.007 0.038 0.8
a Comparison admission ± 6 months.
b Comparison admission ± 12 months.
Table 2. Baseline characteristics and 6- and 12-month deaths or read
limb ischaemia included in the quality of life study.
Revascularisation n 30
Sex men/female 23/7
Age 67/(46±90)
ABPI mean/(range) 0.2/(0±0.6)
Smoking 21 (70%)
Diabetes 19 (63%)
Hypertension 18 (60%)
Hyperlipidemia 8 (27%)
Cardiac disease 9 (30%)
Pulmonary disease 5 (17%)
Renal disease 5 (17%)
Cerebral disease 3 (10%)
Mean (standard deviation).
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popliteal artery, 6 femorodistal bypasses and 3 axillo-
femoral extranatomic grafts. In 6 patients major limb
amputation was performed. In the remaining 16 only
medical treatment was given, associated to 3 minor
amputations, 2 lumbar sympathectomies and 3-
prostaglandin intravenous therapy. There were no
statistically significant differences amongst the three
groups of patients with revascularisation, amputation
and medical treatment, in baseline characteristics
(Table 2).
At 6 months of follow-up there were 4 deaths and
5 major amputations. Between 6 months to 1 year there
were 2 deaths, 4 readmissions and 2 amputations.
No significant differences among treatment groups
were observed in the dimensions of SF-36 question-
naire over the year of study (Table 3). After analysis of
variance with repeated measurements, some dimen-
sions showed significant trends over the follow-up:
bodily pain (p 0.038), vitality (p 0.003), social
functioning (p5 0.001) and mental health (p5 0.001).13 Analysis of variance with repeated measurement comparison.13
neral
alth
Vitality Social
functioning
Role
emotional
Mental
health
57 83 80 69
40 63 23 64
92 15±85 37±100 0±100 20±84
37 57 41 57
±97 0±90 12±100 0±100 16±100
26 39 26 40
±90 15±85 0±100 0±100 28±60
1 0.38 0.1 0.006 0.80
3 0.003 50.001 0.8 50.001
mission by the type of management of patients with critical lower
Amputation n 6 Medical treat n 16 p
3/3 10/6 0.34
70/(59±78) 70/(38±89) 0.64
0.3/(0±0.5) 0.2/(0±0.4) 0.17
3 (50%) 8 (50%) 0.41
3 (50%) 5 (31%) 0.12
2 (33%) 8 (50%) 0.21
1 (17%) 4 (25%) 0.87
2 (33%) 5 (31%) 0.99
0 (0%) 4 (25%) 0.38
0 (0%) 0 (0%) 0.13
0 (0%) 1 (6%) 0.31
Table 3. SF-36 on admission 6 and 12 months in the several groups. Analysis of variance with repeated measurement comparison.
Groups Groups Groups Groups
I II III I II III I II III I II III
Physical functioning Role physical Bodily pain General health
Admission 30 29 30 12 9 7 34 35 34 37 38 33
6 months 35 31 31 55 25 32 31 23 29 38 37 29
12 months 29 24 26 50 20 31 26 21 20 38 35 33
pa 0.88 0.71 0.83 0.82
pb 0.79 0.43 0.77 0.97
Vitality Social functioning Role emotional Mental health
A
Admission 42 38 38 63 66 62 23 24 23 60 67 72
6 months 39 37 33 60 62 50 41 30 46 61 52 50
12 months 27 23 26 42 37 35 28 11 29 41 41 37
pa 0.85 0.79 0.81 0.35
pb 0.91 0.75 0.39 0.33
a Comparison at 6 months in several groups.
b Comparison at 12 months in several groups.
Table 4. Internal consistency SF-36 test.
Dimension Test internal consistency
(alpha of Cronbach)
Physical functioning 0.85
Role physical 0.62
Bodily pain 0.48
General health 0.67
Vitality 0.70
Social functioning 0.60
Role emotional 0.72
Mental health 0.96
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increased at 6 months (p 0.006) but decreased to
basal values at 12 months, whereas role physical
increased at 12 months (p 0.007) and physical func-
tioning and general health remained unchanged over
the 12-months follow-up (Table 1).
As for the internal consistency of the test, all the
dimensions presented a value alpha of Cronbach
greater than 0.5, expected pain (0.48) (Table 4).
Discussion
The main aim of all vascular surgeons performing any
vascular treatment for CLI is limb salvage. However,
the influence of the ischaemic diseased limb on
patient's daily life is seldom taken into account. We
tried to assess whether QOL in CLI patients shows
any relationship with the type of treatment. The
number of papers examining QOL in CLI is lim-
ited,14,15 and the relative impact of different treat-
ments is rarely evaluated.16±21 In the present study,there appeared to be no relationship between
treatment group and changes in SF-36 between admis-
sion and 12 months.
This may be explained by the fact that associated co-
morbidity worsens QOL over time regardless of the
success or failure of treating the ischaemic limb itself.
In conclusion, our results suggest that changes in
dimensions of QOL obtained by limb revascular-
isation do not differ from those of other therapeu-
tic approaches after the triage for candidates for
the former has been done. Quality of life of CLI pa-
tients is worse than that of healthy population and
tends to decay over one year, particularly for mental
components.
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